Traitements intrapéritonéaux de la carcinose ovarienne : proposition d’algorithmes décisionnels [Intraperitoneal therapy for carcinomatosis in ovarian cancer: proposed treatment algorithm]
Fiche du document
18 mai 2022
- doi: 10.53738/REVMED.2022.18.782.990
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.782.990
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35583278
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_521D9B8BA7341
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Drug therapy PharmacotherapyCiter ce document
M. Undurraga et al., « Traitements intrapéritonéaux de la carcinose ovarienne : proposition d’algorithmes décisionnels [Intraperitoneal therapy for carcinomatosis in ovarian cancer: proposed treatment algorithm] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.782.990
Métriques
Partage / Export
Résumé
Ovarian cancer is the first cause of death by gynecological cancer. Most of the patients are diagnosed with peritoneal carcinomatosis that represents a therapeutic challenge. Its management implies maximal cytoreductive surgery with survival benefit. Over the last three decades, several strategies of intra-peritoneal chemotherapy have been investigated. This includes intra-peritoneal adjuvant chemotherapy that is used mainly in North America, hyperthermic intraperitoneal chemotherapy (HIPEC) and more recently pressurized intraperitoneal aerosol chemotherapy (PIPAC). In the current article, we review the evidence in favor of each therapeutic approach, and we propose treatment algorithms depending on the clinical situation of ovarian cancer patients: upfront, platinum-sensitive and platinum-resistant relapse.